Abstract:Adolescents and young adults (AYA) with myeloproliferative neoplasms (MPN) demonstrate notable differences compared to older patients with MPN. With the most common MPN in this group being essential thrombocythaemia, patients are predominantly female, have a higher incidence of CALR mutations and demonstrate a predilection for splanchnic vein thrombosis. While their overall survival is superior compared to older adults, they remain at risk for transformation to more aggressive disease states, and priorities in treatment should target not only symptom burden and thrombotic risk reduction but also disease modification. Unique considerations in their care include pregnancy/fertility‐related issues as well as navigating psychosocial burdens. Summary Myeloproliferative neoplasms (MPN) are characterized by a clonal proliferation of myeloid lineage cells within the bone marrow. The classical BCR‐ABL negative MPNs are comprised of polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. Historically, the majority of MPNs are diagnosed in adults older than 60 years of age; however, in recent years, there has been recognition of MPNs in the adolescent and young adult (AYA) population. AYAs with MPN, typically defined as between the ages of 15 and 39 years old, may comprise up to 20% of patients diagnosed with MPN. They demonstrate unique patterns of driver mutations and thrombotic events and remain at risk for progression to more aggressive disease states. Given the likely long length of time they will live with their disease, there is a significant unmet need in identifying well‐tolerated and effective treatment options for these patients, particularly with the advent of disease modification. In this review, we provide a comprehensive overview of the clinical features, disease course and management of AYA patients with MPN and, in doing so, highlight key characteristics that distinguish them from their older counterparts.

Myeloproliferative neoplasms: young patients, current data and future considerations

Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs

Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature

Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study

Biological Markers of Myeloproliferative Neoplasms in Children, Adolescents and Young Adults

Advances in understanding and management of myeloproliferative neoplasms

[Clinical and Genetic Characteristics of Young Patients with Myeloproliferative Neoplasms].

Experimental therapeutics for patients with myeloproliferative neoplasias

Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia

Clinical Characteristics, Cytogenetic Risks, and Prognoses of Young Multiple Myeloma Patients in the Era of Novel Therapies

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms

Patient-Reported Outcomes in Young Adults with Myeloproliferative Neoplasms

New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?

Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012

Pathogenesis and management of high molecular risk myeloproliferative neoplasms

Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs

Current myeloproliferative neoplasm scoring systems for clinical practice

Evolution of myeloproliferative neoplasms from normal blood stem cells

Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)

Calr Vs. JAK2 Vs. MPL Mutations in the Progression of Philadelphia-Negative Myeloproliferative Neoplasms

Advances in molecular evaluation of myeloproliferative neoplasms